22 March 2018 - - Austin, Texas-based clinical trial access improvement company Elligo Health Research has raised USD 16m in series B funding led by Hatteras Venture Partners and Noro-Moseley Partners with participation from FS Healthcare LLC, Excelerate Health Ventures, and all existing series A investors including Shumway Capital, the company said.

Elligo improves clinical trial access by engaging the 97% of physicians currently not offering clinical research to their patients.

It offers the only platform that brings clinical research to the clinic, accelerating the development of new pharmaceutical, biotechnology and medical device products and therapies.

Elligo 'Goes Direct' with an approach that uses electronic health records and other health data to identify real-world patients and physicians for participation in clinical studies.

It is the company's mission to support health care providers by providing personnel, procedures, technology and infrastructure for clinical research, enabling patients to participate in research while remaining under the care of their own trusted physician.